

MIT\7762\trans-not2.com
TAD3
DEB/TAD
1/6/99



w/d

4P1648 # & Box seq
PATENT APPLICATION
Docket No.: MIT-7762
RECEIVED

JAN 19 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Shuguang Zhang, Alexander Rich, Lin Yan and George Whitesides
Application No.: 08/882,415 Group: 1648
Filed: June 25, 1997 Examiner: P. Achutamurthy
For: SELF-ASSEMBLY PEPTIDE SURFACES FOR CELL PATTERNING
AND INTERACTIONS

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>1/8/99</u>	<u>Jean Hibino</u>
Date	Signature
Jean Hibino	
Typed or printed name of person signing certificate	

TRANSMITTAL OF SEQUENCE LISTING AND
PRELIMINARY AMENDMENT IN RESPONSE TO NOTICE TO COMPLY
WITH 37 C.F.R. §§1.821-1.825

Box Sequence

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

This amendment is submitted in response to the Notice to Comply with Sequence Rules 37 C.F.R. §§1.821-1.825 attached thereto, mailed from the Patent Office on July 8, 1998, a copy of which is attached.

Applicants' Attorney requests a three-month extension of time to respond to the Notice. A Petition for the Extension and the appropriate fees are being filed concurrently.

Transmitted herewith is a copy of the "Sequence Listing" (sheets 1/2 through

X

2/2) in paper form for the above-identified patent application as required by 37 C.F.R. §1.821(c) and a copy of the "Sequence Listing" in computer readable form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Applicants' Attorney submits the following amendments to comply with 37 C.F.R. §1.825:

In the Specification

Please insert the attached "Sequence Listing" (sheets 1/2 through 2/2), and comprising SEQ ID NOS: 1, 2, 3, 4 and 5, into the above-referenced application.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By David E. Brook

David E. Brook

Registration No. 22,592

Telephone (781) 861-6240

Facsimile (781) 861-9540


Lexington, Massachusetts 02421-4799

Date: 1/7/99

K

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



☒ 1. This application clearly fails to comply with the requirements of 37 CFR - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☐ 7.

Other: _____

Applicant must provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.